Lipid-related markers and cardiovascular disease prediction.
about
Characterization of a novel endothelial biosensor assay reveals increased cumulative serum inflammatory potential in stabilized coronary artery disease patientsTriglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?Derivation and assessment of risk prediction models using case-cohort data.Assessing risk prediction models using individual participant data from multiple studiesLipid, blood pressure and kidney update 2013.Long-term Expression of Apolipoprotein B mRNA-specific Hammerhead Ribozyme via scAAV8.2 Vector Inhibits Atherosclerosis in Mice.Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity.Serum lipids, apolipoproteins, and mortality among coronary artery disease patientsAn assessment of the relationship between clinical utility and predictive ability measures and the impact of mean risk in the population.A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.Cardiometabolic risk assessments by body mass index z-score or waist-to-height ratio in a multiethnic sample of sixth-graders.Glycated hemoglobin measurement and prediction of cardiovascular disease.Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.The association between Mediterranean Diet Score and glucokinase regulatory protein gene variation on the markers of cardiometabolic risk: an analysis in the European Prospective Investigation into Cancer (EPIC)-Norfolk studyElevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development.Prevalence of dyslipidemia and its association with insomnia in a community based population in ChinaGenetic risk prediction and a 2-stage risk screening strategy for coronary heart diseaseApolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.Biomarkers of cardiovascular disease risk in women.HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients.Risk profiles for aortic dissection and ruptured or surgically treated aneurysms: a prospective cohort study.Prevalence and incidence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis protocolJoint associations of folate, homocysteine and MTHFR, MTR and MTRR gene polymorphisms with dyslipidemia in a Chinese hypertensive population: a cross-sectional studyGenetically determined height and coronary artery disease.Hyperlipidemia as a risk factor for cardiovascular disease.Roles of High-Density Lipoprotein Cholesterol in Patients With Acute Myocardial Infarction.Hazardous alcohol consumption is associated with increased levels of B-type natriuretic peptide: evidence from two population-based studies.Comparison of absolute serum creatinine changes versus Kidney Disease: Improving Global Outcomes consensus definitions for characterizing stages of acute kidney injury.Divergent pathway of lipid profile components for cardiovascular disease and mortality events: Results of over a decade follow-up among Iranian population.Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective studyMonitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapyGuidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Impact of low high-density lipoprotein-cholesterol level on 2-year clinical outcomes after acute myocardial infarction in patients with diabetes mellitus.Cardiovascular disease risk prediction in women: is there a role for novel biomarkers?Serum concentrations of cholesterol, apolipoprotein A-I and apolipoprotein B in a total of 1694 meat-eaters, fish-eaters, vegetarians and vegansLipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).Relationship between outdoor temperature and cardiovascular disease risk factors in older people.Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.Is lipoprotein-associated phospholipase A₂ correlated with cardiovascular risk in European women?
P2860
Q23913506-C0B42A73-11D6-46F0-B4E6-58FD5171A153Q26746279-EBB24FF0-B43F-4C64-B82F-E8C6FE79F3E1Q30666727-2BAE17A4-66F8-4423-B3EF-B21C171FA4F8Q30724002-1B594B78-F9FF-49B8-AACD-4ED432C898ACQ33574532-D394E1CF-944E-4D85-9644-791A48967FC6Q33635929-7C4C778E-1F6C-480B-A89F-587BB14F7B36Q33672059-77AD8FAC-3036-4C71-AE33-8FE32C734807Q33760061-0589D995-20FE-4371-BC22-880BB27C110FQ33926791-9BB329AB-965C-455E-810A-01457F2EFCCFQ33931813-4EDF5A6F-1573-423A-90A9-966398463E51Q34009642-ACDD4EA7-2432-4C03-AECC-CAB96FB84EA6Q34040328-465F8F66-7576-4445-BEED-FC98447BE37CQ34072528-1A8B8AFC-B2E1-4BA9-92EB-C190D4ABBE2EQ34241663-1007C1CC-BABD-4FF8-B08C-98CC214B6990Q34315320-42078133-3BF4-4AA8-AAD7-388C6E1883C3Q34339877-1D4A5C88-8BA7-46BD-B1A8-0D2B8FA8353AQ34411343-1AF6DF1D-101C-49E0-9E00-C8E2CD9448FFQ34568807-D4579C08-87BB-4B52-9034-B19255CF1526Q35025720-9F8132D2-5EB1-48CD-AE01-E5C7AB21DACDQ35027220-2B5D9227-299B-40BD-8EC1-85DBA84565FCQ35088173-D86E23E6-4BE8-4BB9-BAEF-990F353CD375Q35203712-9635E189-CB95-4CB5-B8F5-F325EE1C281BQ36023213-53EC4B38-6E87-4F7B-8BB6-BFB3D98CA5F6Q36288162-1D659F71-8C59-48A7-AB5A-CB8C3E999407Q36609968-63A5885A-2C9C-4B6D-90BE-AA6ED98967AAQ36891753-5FD53B1B-A1FF-4A09-92E2-A35189212DC9Q36902446-1B4FB35E-3E17-47F3-BC4F-8DF936321726Q36936583-56055C9F-2104-475C-BFEC-51C67CE6A5DFQ37035438-3FD614ED-6AD4-446F-B6A9-701259E67874Q37076194-9CC868A5-BD09-4CF4-9D5E-A7A3A479DF22Q37093147-CD86D00C-B7FD-4C50-9E20-4356B10E0BDFQ37115301-4207C7C3-98AD-4C39-8879-F8F4E725A992Q37251490-FDBB2BBC-FFAC-494E-B10C-71C8AA481A5CQ37424006-5622227E-2633-4981-876F-2E52F76120F6Q37424605-0B2D60AC-DB6D-4DF2-9028-82174F2928C6Q37562638-66EBADE4-BD1C-4D4B-807D-E42A049F246AQ37623853-48A869A6-9C2C-43B4-90C2-0D2E600689C9Q37635465-B60154FE-C301-4801-A79D-E5CE5E175069Q37677889-7B9E756A-5794-4674-98EF-EE51BEBB6333Q37690809-5CA15552-8211-48C8-82FF-51B5DB8B1BFB
P2860
Lipid-related markers and cardiovascular disease prediction.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Lipid-related markers and cardiovascular disease prediction
@nl
Lipid-related markers and cardiovascular disease prediction.
@ast
Lipid-related markers and cardiovascular disease prediction.
@en
type
label
Lipid-related markers and cardiovascular disease prediction
@nl
Lipid-related markers and cardiovascular disease prediction.
@ast
Lipid-related markers and cardiovascular disease prediction.
@en
prefLabel
Lipid-related markers and cardiovascular disease prediction
@nl
Lipid-related markers and cardiovascular disease prediction.
@ast
Lipid-related markers and cardiovascular disease prediction.
@en
P2093
P2860
P50
P3181
P356
P1476
Lipid-related markers and cardiovascular disease prediction.
@en
P2093
Agustín Gómez-de-la-Cámara
Alexander Thompson
Altan Onat
Angela M Wood
Chris Packard
Christie M Ballantyne
Daan Kromhout
David Wormser
Dorothea Nagel
Edoardo Casiglia
P2860
P304
P3181
P356
10.1001/JAMA.2012.6571
P407
P50
P577
2012-06-01T00:00:00Z